iRhythm Technologies (NASDAQ:IRTC – Free Report) had its price objective trimmed by Needham & Company LLC from $119.00 to $96.00 in a research note released on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock.
Several other research analysts have also recently issued reports on IRTC. Canaccord Genuity Group increased their price objective on iRhythm Technologies from $122.00 to $137.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. JPMorgan Chase & Co. cut their price objective on iRhythm Technologies from $133.00 to $100.00 and set an “overweight” rating for the company in a research report on Friday, August 2nd. Oppenheimer cut their price objective on iRhythm Technologies from $165.00 to $145.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Morgan Stanley lowered their target price on iRhythm Technologies from $135.00 to $130.00 and set an “overweight” rating on the stock in a report on Monday, July 15th. Finally, StockNews.com lowered iRhythm Technologies from a “hold” rating to a “sell” rating in a report on Friday, September 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $108.50.
Check Out Our Latest Analysis on iRhythm Technologies
iRhythm Technologies Price Performance
iRhythm Technologies (NASDAQ:IRTC – Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.71). iRhythm Technologies had a negative return on equity of 120.86% and a negative net margin of 26.90%. The company had revenue of $147.54 million for the quarter, compared to analysts’ expectations of $146.69 million. During the same quarter last year, the company earned ($0.89) EPS. iRhythm Technologies’s revenue for the quarter was up 18.4% compared to the same quarter last year. Equities analysts predict that iRhythm Technologies will post -2.66 earnings per share for the current year.
Insider Buying and Selling
In other news, CFO Brice Bobzien sold 1,372 shares of the firm’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $70.34, for a total value of $96,506.48. Following the transaction, the chief financial officer now directly owns 24,428 shares in the company, valued at $1,718,265.52. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.68% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On iRhythm Technologies
A number of hedge funds have recently bought and sold shares of IRTC. Westfield Capital Management Co. LP acquired a new stake in iRhythm Technologies during the 1st quarter valued at approximately $58,311,000. Champlain Investment Partners LLC grew its stake in iRhythm Technologies by 104.1% during the 1st quarter. Champlain Investment Partners LLC now owns 575,800 shares of the company’s stock valued at $66,793,000 after purchasing an additional 293,710 shares in the last quarter. First Light Asset Management LLC grew its stake in iRhythm Technologies by 176.8% during the 1st quarter. First Light Asset Management LLC now owns 420,892 shares of the company’s stock valued at $48,823,000 after purchasing an additional 268,829 shares in the last quarter. Mackenzie Financial Corp grew its stake in iRhythm Technologies by 5.9% during the 2nd quarter. Mackenzie Financial Corp now owns 1,428,324 shares of the company’s stock valued at $153,745,000 after purchasing an additional 80,091 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in iRhythm Technologies by 14.5% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 511,905 shares of the company’s stock valued at $59,381,000 after purchasing an additional 64,755 shares in the last quarter.
About iRhythm Technologies
iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Read More
- Five stocks we like better than iRhythm Technologies
- Buy P&G Now, Before It Sets A New All-Time High
- November’s Small-Cap Treasures: 3 Stocks Poised for Growth
- Are Penny Stocks a Good Fit for Your Portfolio?
- Bright Future for Clean Hydrogen Stocks? Analysts Are Watching
- What is the Nasdaq? Complete Overview with History
- High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight
Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.